Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-methanesulfonyl-3-(1-methyl-5-nitroimidazol-2-yl)-2-imidazolidinone
2. Cg-10213-go
3. Go 10213
4. Go-10213
1. 56302-13-7
2. Satranidazole [inn]
3. 1-(1-methyl-5-nitroimidazol-2-yl)-3-methylsulfonylimidazolidin-2-one
4. 1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)-2-imidazolidinone
5. 4n7g8a6439
6. Satranidazol
7. Satranidazol [spanish]
8. Satranidazolum
9. Satranidazolum [latin]
10. 1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)imidazolidin-2-one
11. Go 10213
12. C 10213 Go
13. Go-10213
14. Brn 0848345
15. Unii-4n7g8a6439
16. 1-methylsulfonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone
17. 2-imidazolidinone, 1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)-
18. 5-25-09-00447 (beilstein Handbook Reference)
19. Satranidazole [mart.]
20. Satranidazole [who-dd]
21. Schembl1682863
22. Chembl2105542
23. Dtxsid60204840
24. C-10213-go
25. Zinc4217442
26. 1-(1-methyl-5-nitroimidazol-2-yl)-3-(methylsulfonyl)-2-imidazolidinone
27. A924024
28. Q27260233
29. 3-(1-methyl-5-nitroimidazol-2-yl)-1-methylsulfonyl-imidazolidin-2-one
| Molecular Weight | 289.27 g/mol |
|---|---|
| Molecular Formula | C8H11N5O5S |
| XLogP3 | -0.8 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Exact Mass | 289.04808964 g/mol |
| Monoisotopic Mass | 289.04808964 g/mol |
| Topological Polar Surface Area | 130 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 497 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Market Place
ABOUT THIS PAGE
A Satranidazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Satranidazole, including repackagers and relabelers. The FDA regulates Satranidazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Satranidazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Satranidazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Satranidazole supplier is an individual or a company that provides Satranidazole active pharmaceutical ingredient (API) or Satranidazole finished formulations upon request. The Satranidazole suppliers may include Satranidazole API manufacturers, exporters, distributors and traders.
click here to find a list of Satranidazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Satranidazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Satranidazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Satranidazole GMP manufacturer or Satranidazole GMP API supplier for your needs.
A Satranidazole CoA (Certificate of Analysis) is a formal document that attests to Satranidazole's compliance with Satranidazole specifications and serves as a tool for batch-level quality control.
Satranidazole CoA mostly includes findings from lab analyses of a specific batch. For each Satranidazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Satranidazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Satranidazole EP), Satranidazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Satranidazole USP).
LOOKING FOR A SUPPLIER?
